MedPath

Effect of Dexmedetomidine in Preventing Cough and Postoperative Pain After Laryngeal Surgery for Cancer

Not Applicable
Conditions
Laryngectomy; Status
Interventions
Registration Number
NCT03918889
Lead Sponsor
Eye & ENT Hospital of Fudan University
Brief Summary

Background: During emergence from anesthesia for partial and total laryngectomy, severe airway reflex and systemic hypertension during recovery may lead to pneumoderm, hemorrhage, pneumomediastinum or pneumothorax. Dexmedetomidine is a selective α2-adrenoreceptor agonist that has sedative, analgesic, and sympatholytic properties. It has been reported dexmedetomidine can attenuate coughing reflex and prevent emergence agitation without delaying recovery and respiratory depression from general anesthesia. The purpose of this study was to investigate the effect of dexmedetomidine compared with midazolam on cough suppression and recovery quality during emergence from general anesthesia after partial and total laryngectomy.

Methods American Society of Anesthesiologists physical status I-II male adults undergoing elective laryngectomy under sevoflurane anesthesia were recruiting and randomly allocated to receive either dexmedetomidine(Group D, n = 60) infusion at 0.5 µg•kg-1 for 10 min before tracheotomy, then adjusted to 0.3µg•kg-1•h-1 or midazolam (Group M, n = 60) infusion at 0.05 mg•kg-1 ten minutes before tracheotomy, then adjusted to 0.02mg•kg-1•h-1. The primary outcome measure was the incidence and severity of cough. Hemodynamics, pain intensity \[Visual Analogue Scale (VAS)\] and Ramsay sedation scale (RSS) were also evaluated at awake, patients returning to ward from post anesthesia care unit (PACU),2h after surgery. postoperative sufentanil consumption, recovery time and the incidence of concerning adverse effects were recorded.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
120
Inclusion Criteria

Subject scheduled for partial or total laryngectomy.

Exclusion Criteria

Subject has respiratory disease; Subject has pharyngeal paraganglioma; Subject has cardiac disease; Uncontrolled hypertension; Subject has been taking β-adrenoreceptor blockers; Long-term abuse of alcohol (>6 months),opioids, or sedative-hypnotic drugs; Allergic to dexmedetomidine or midazolam; Subject has neuropsychiatric diseases; Operation time shorter than 1 h or longer than 4 h.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
dexmedetomidineDexmedetomidine Injectable Productpatients receive dexmedetomidine infusion
midazolamMidazolam injectionpatients receive midazolam infusion
Primary Outcome Measures
NameTimeMethod
The severity of coughTime0:2hours after surgery

Coughing severity was classified using the 3-point scale.:1=mild (single) cough, 2=moderate (≤5 s) cough, and 3=severe (\>5 s) cough.

Secondary Outcome Measures
NameTimeMethod
HRTime7:0 minute after departure from the PACU

Heart rate

SpO2Time7:0 minute after departure from the PACU

Oxygen saturation using pulse oximetry

SBPTime7:0 minute after departure from the PACU

Systolic blood pressure

the incidence of adverse effectsTime0:2hours after surgery

desaturation,shivering,drowsiness, delirium,hypertension,hypotension,itching,arrhythmia,respiratory depression

BDPTime7:0 minute after departure from the PACU

Diastolic blood pressure

Pain intensityTime0:2hours after surgery

Assessed by Visual Analogue Scale (VAS), (0, no pain; 10, the worst pain intolerable)

SedationTime0: 2hours after surgery

Assessed by Ramsay sedation scale (RSS),1, Anxious or restless or both,2, Cooperative, orientated and tranquil,3,Responding to commands,4,Brisk response to stimulus,5,Sluggish response to stimulus,6, No response to stimulus.

DBPTime6:0 minute after awareness

Diastolic blood pressure

Trial Locations

Locations (1)

Department of Anesthes iology, The Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai Medical College of Fudan University

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath